Abstract
This review describes gene therapy strategies that take advantage of defective signal transduction pathways to selectively kill cancer cells without adversely affecting normal cells. The distinctive features of cancer cells currently exploited by gene therapy include mitosis, cell permissiveness to infection, specific protease activity, and the activity of the p53, Rb / E2F and wnt / catenin signal transduction pathways. In most cases, proof of concept has been obtained in vitro and in vivo, but only a few approaches made it to the clinic. Overall, the clinical success rate has been disappointing and it is concluded that the gene therapy of cancer requires more innovation and hard work before its potential can be fully realized.
Keywords: cancer cells, gene therapy strategies, proliferation, susceptibility to infection, protease activity, oncolytic adenoviruses
Current Pharmaceutical Design
Title: Gene Therapy Approaches for the Selective Killing of Cancer Cells
Volume: 8 Issue: 19
Author(s): Eva Maria Westphal and Harald von Melchner
Affiliation:
Keywords: cancer cells, gene therapy strategies, proliferation, susceptibility to infection, protease activity, oncolytic adenoviruses
Abstract: This review describes gene therapy strategies that take advantage of defective signal transduction pathways to selectively kill cancer cells without adversely affecting normal cells. The distinctive features of cancer cells currently exploited by gene therapy include mitosis, cell permissiveness to infection, specific protease activity, and the activity of the p53, Rb / E2F and wnt / catenin signal transduction pathways. In most cases, proof of concept has been obtained in vitro and in vivo, but only a few approaches made it to the clinic. Overall, the clinical success rate has been disappointing and it is concluded that the gene therapy of cancer requires more innovation and hard work before its potential can be fully realized.
Export Options
About this article
Cite this article as:
Westphal Maria Eva and von Melchner Harald, Gene Therapy Approaches for the Selective Killing of Cancer Cells, Current Pharmaceutical Design 2002; 8 (19) . https://dx.doi.org/10.2174/1381612023393927
DOI https://dx.doi.org/10.2174/1381612023393927 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer and Stem Cells
Current Cancer Therapy Reviews Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Nanotechnology Platforms in Diagnosis and Treatment of Primary Brain Tumors
Recent Patents on Nanotechnology In vivo Evaluation and Alzheimer’s Disease Treatment Outcome of siRNA Loaded Dual Targeting Drug Delivery System
Current Pharmaceutical Biotechnology Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry ZIP4 is a Novel Diagnostic and Prognostic Marker in Human Pancreatic Cancer: A Systemic Comparison Between EUS-FNA and Surgical Specimens
Current Molecular Medicine Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Therapy Based on the Regulation of Thiol-dependent Redox Systems
Current Medicinal Chemistry Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Current Stem Cell Research & Therapy A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Current Cancer Drug Targets Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment
Clinical Cancer Drugs Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry The Application of Nanomaterials in Stem Cell Therapy for Some Neurological Diseases
Current Drug Targets Current Development of Metal Complexes with Diamine Ligands as Potential Anticancer Agents
Current Medicinal Chemistry TGF-Beta: a Master Switch in Tumor Immunity
Current Pharmaceutical Design Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
Current Cancer Drug Targets Metabotropic Glutamate Receptors in the Trafficking of Ionotropic Glutamate and GABAA Receptors at Central Synapses
Current Neuropharmacology Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology